Immune therapy for stopping HIV treatment safely
Treatments studied
Part of Infections clinical trials.
This trial tests if two drugs, baricitinib and sirolimus, can help control HIV after stopping standard antiretroviral therapy (ART). It aims to see if these immune treatments allow patients to maintain viral suppression without daily pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and weigh between 110 and 220 pounds.
- You were diagnosed with HIV during the early stage (within 3 months of infection) and started ART within 2 months of that diagnosis.
- You have been on HIV medicines (like dolutegravir, bictegravir, raltegravir, or rilpivirine) for at least a year and have had undetectable virus for the last 6 months.
- Your CD4 count (immune cells) is above 500 on recent tests.
- You are willing to stop your HIV medicines for a short period (treatment interruption) and follow a strict visit schedule.
- You agree to take valacyclovir (to prevent herpes) daily during the interruption and use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
This trial tests two lab-made antibodies that may help control HIV without daily pills. It is for people who started HIV treatment very early and now take a break from their regular meds under close monitoring.
This study tests if adding the drug baricitinib to your regular HIV treatment can reduce the amount of virus hiding in your body, which might help control HIV better or even lead to a cure.
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.